ACE-031 Research Indications
Peer-reviewed research has investigated ACE-031 across 5 indications in 2 categories.
Research Indications by Category
Muscle Growth
| Indication | Effectiveness | Description |
|---|---|---|
| Muscle Hypertrophy | most effective | Phase 1 data showed statistically significant lean mass increases (average +1.7%) after a single IV dose in healthy postmenopausal women. |
| Muscular Dystrophy | effective | Phase 2 trial in DMD patients showed improvements in lean body mass and bone mineral density, but trial was halted due to vascular adverse events. |
| Muscle Wasting / Cachexia | effective | Preclinical models demonstrate robust prevention of muscle loss in disease states through myostatin pathway inhibition. |
Body Composition
| Indication | Effectiveness | Description |
|---|---|---|
| Fat Loss | effective | Phase 1 trial subjects showed concurrent fat mass reductions alongside lean mass gains, suggesting favorable nutrient partitioning. |
| Bone Density | moderate | DMD trial data showed increases in bone mineral density, consistent with known effects of ActRIIB pathway modulation on bone metabolism. |
Related Sections
- Overview: What Is ACE-031?
Deep Dives: Key Benefits | Mechanism of Action | Dosing Protocols | Side Effects & Safety | Interactions & Stacking | What to Expect Timeline | FAQ | References & Studies | Quality Checklist
Product: ACE-031 — ≥98% (HPLC verified) · COA available · 1mg
Disclaimer: This compound is supplied for qualified research and laboratory purposes only. Not for human consumption, therapeutic use, or any application outside controlled research environments.
RaysunPeptide — Southeast Asia-based peptide manufacturer supplying research-grade compounds with HPLC/MS verification and Certificates of Analysis. B2B and qualified research applications.